---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-001097"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:33:19.588207+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TransCode publishes preclinical data showing TTX-MC138 improves survival in glioblastoma models

## Summary
- Study in Journal of Functional Biomaterials shows TTX-MC138 delivered to GBM tumors after IV injection.
- TTX-MC138 induced 5-fold increase in apoptotic activity and statistically significant survival extension.
- IND-enabling studies completed; TTX-MC138 already in Phase 1a for metastatic solid tumors.
- Phase 2a clinical trial for TTX-MC138 anticipated to begin in first half of 2026.

## SEC filing metadata
- accession: 0001104659-26-001097
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926001097/0001104659-26-001097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926001097/tm261878d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-001097
- JSON: https://secwatch.observer/filing/0001104659-26-001097.json
- Plain text: https://secwatch.observer/filing/0001104659-26-001097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.